INS1202 for Amyotrophic Lateral Sclerosis (ALS)
A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)
- Age
- 18 – 79
- Sex
- Any
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 23 (estimated)
- Sponsor
- Insmed Gene Therapy LLC · Industry
This trial is looking for adults aged 18 to 79 with ALS. Participants will receive a single injection of INS1202 and we will observe how safe it is and how it affects their condition.
You may be able to join if
- I have a body mass index (BMI) of 18 or higher.
- I have been diagnosed with ALS.
- I have a positive test for a SOD1 mutation or no known ALS-related genetic mutation.
- I have a score of 24 or higher on the ALSFRS-R assessment.
- My ALS symptoms started no more than 42 months ago.
You may not be able to join if
- I have received cellular or gene therapies for ALS before.
- I am currently taking any experimental medications for ALS or other conditions.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.
Loading trial locations…